Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC303 subcutaneous injection in immune-mediated glomerular diseases (Phase I/II)
CTR20252297Phase 2Active
- Sponsor
- Mab-Venture Biopharma
- Start
- Jun 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MBS303 in immune-mediated glomerulonephritis, idiopathic membranous glomerulonephritis (IMG), IgA nephropathy (IgAN), nephrosis, anti-glomerular basement membrane disease, sponsored by Mab-Venture Biopharma. Started Jun 2025; status: active.
02
Drugs
MBS303
03
Conditions
immune-mediated glomerulonephritisidiopathic membranous glomerulonephritis (IMG)IgA nephropathy (IgAN)nephrosisanti-glomerular basement membrane disease
Beyond the preview
Go deeper on CTR20252297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252297.